Electrolux: President and CEO Hans Stråberg`s Comments on the Second-Quarter Results of 2010

We are on track and presenting a record Q2 result

We are on track and can today present a margin of 6.5% for the latest 12-month
period. All business areas show improved profitability. We are selling more
advanced products and are step by step improving our position in the important
premium segment. Cash flow continues to be strong, which has further
strengthened our balance sheet.
STOCKHOLM–(Business Wire)–
We are implementing our strategy, based on innovative products, a strong
Electrolux brand and low production costs. In North America, we have improved
our product mix due to the fact that we have successfully increased sales and
gained market shares under our own strong Electrolux and Frigidaire brands. I am
especially satisfied with the performance in North America considering the fact
that we had extra costs amounting to about SEK 200m in the quarter related to
the re-launch of Frigidaire and the consolidation of the Group`s North American
headquarters to Charlotte.

The US government rebates to stimulate sales of energy-efficient products have
contributed to strong growth, especially in the month of April. I think there is
a learning for other countries on how to reduce energy-consumption in an
efficient way. I also believe we will see a continued growth in North America in
the coming years, as many American consumers need to replace their old
appliances, which are beginning to reach the end of their life cycles.

In Europe as well, we improved our product mix and continued to sell more in the
very important built-in segment. We will continue to introduce new products to
the European market, and in order to secure the success of the product launches,
we will increase marketing investments in the second half of 2010.

The operations in Latin America, Asia Pacific and for Professional Products
succeeded in nearly doubling their earnings compared to the second quarter of
2009. Asia Pacific showed its best result ever, and margin increased to 10%. In
spite of a very tough period, Professional Products reached an operating margin
of 12%. This is also a record.

We continue to generate a very strong cash flow, which has further strengthened
our balance sheet. This gives us opportunities to continue to deliver a strong
return to our shareholders.

Although there is still great uncertainty and many things can happen in the
remaining part of the year, I still think 2010 could be the year we approach our
goal of an operating margin of 6% with continued improved capital efficiency.

Stockholm, July 19, 2010

Hans Stråberg
President and Chief Executive Officer

This information was brought to you by Cision http://www.cisionwire.com

Electrolux
Peter Nyquist, +46 (0)8 738 60 03
Head of Investor Relations and Financial Information

Copyright Business Wire 2010

Swedish Orphan Biovitrum and Dongbao announce Commercial Alliance for the Chinese and European markets

STOCKHOLM, SWEDEN, Jul 06 (MARKET WIRE) —

Stockholm, Sweden and Tonghua, China – July 6, 2010 – Swedish Orphan
Biovitrum (STO: SOBI) and Dongbao today announced their intent to form a
strategic Commercial Alliance. In such an alliance, Swedish Orphan
Biovitrum would be the marketing and sales partner of choice for
Dongbao’s pipeline of Biopharmaceuticals and other drugs in Europe and
Dongbao would be the marketing and sales partner of choice for Swedish
Orphan Biovitrum’s marketed and pipeline products in China.

The announced Commercial Alliance would be a partnership where both
parties will benefit in two ways. First, each party secures a marketing
and sales partner for its own products in an important new territory,
China in the case of Swedish Orphan Biovitrum and Europe in the case of
Dongbao. Second, each party gains access to a new portfolio of exciting
products for its home markets.

The parties also announced that they intend to complete the first stage of
the Commercial Alliance by completing ongoing negotiations regarding the
following products:

* Iron Sucrose from Dongbao where Swedish Orphan Biovitrum will be the
exclusive marketing and sales partner in Europe for this product.

* Kineret and the late stage development project Kiobrina from Swedish
Orphan Biovitrum where Dongbao will be the exclusive marketing and sales
partner in China for these products.

Swedish Orphan Biovitrum intends to deepen its collaboration with Dongbao,
including its affiliate Rechon Life Science Group, as regards
manufacturing services.

An alliance will address current pharmaceutical market trends in both
China and Europe. The Chinese pharmaceutical market is large and rapidly
growing. It is also becoming more and more receptive to high value,
innovative products that meet significant unmet medical needs. Thus,
Swedish Orphan Biovitrum’s products are a good fit with the strong and
growing high value, specialty segment of the Chinese market. Similarly,
the Biosuperior segment of the European pharmaceutical market is rapidly
growing. Again, this makes market entry in Europe for Dongbao’s portfolio
of Biosuperiors timely and in-line with regional trends.

Martin Nicklasson, CEO of Swedish Orphan Biovitrum stated “We are very
pleased to have identified a partner in Dongbao with a successful track
record of selling high value biotechnology products in China. Dongbao has
a deep understanding of biotechnology products from a manufacturing and
clinical development perspective. Moreover, they have an impressive track
record of success in regulatory affairs as well as in marketing and
sales. Thus, we see Dongbao as the perfect partner to help Swedish Orphan
Biovitrum to realize the significant opportunity for our products in the
Chinese market.

Additionally, we are excited about gaining access to Dongbao’s pipeline of
high value Biosuperiors. We look forward to working with these products
over the long term to realize the full commercial potential of these
products in Europe.”

Dr. Zhaoqi Li, Vice President of Dongbao Enterprise Group and the Chairman
of the Board of Rechon Life Science Group expressed that “A fast growing
Chinese market is now offering great opportunity for innovative and high
value pharmaceutical products. We admire Swedish Orphan Biovitrum’s
remarkable efforts and achievements in the development of specialist
pharmaceutical products for rare diseases. We will contribute, with the
best of our effort, to the successful introduction of Swedish Orphan
Biovitrum’s product into the Chinese market as well as into the emerging
markets where Dongbao/Rechon already have a strong network established.

It has been a very interesting journey made by Dongbao in the development
of high value biotech products. By combining Swedish Orphan Biovitrum’s
knowledge, experience and market network with Dongbao’s interesting range
of biotech products we will have a prosperous future in Europe.

Partnership has always been important for Dongbao’s business success. The
establishment of a strong collaboration with Swedish Orphan Biovitrum will
add good value for our future development. We are very excited that such a
Commercial Alliance with Swedish Orphan Biovitrum will enable smooth
access of our products into the European market and, in the other
direction, we are very pleased to offer our support for the successful
entry of Swedish Orphan Biovitrum’s products into the Chinese market.”

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical
company with an international market presence. The company is focused on
providing and developing specialist pharmaceuticals for rare disease
patients with high medical needs. The portfolio consists of about 60
marketed products and an emerging late stage clinical development
pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune
diseases, fat malabsorption, cancer supportive care and inherited
metabolic disorders.

Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and
approximately 500 employees. The head office is located in Sweden and the
share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information
please visit www.sobi.com.

For more information please contact: Swedish Orphan Biovitrum AB (publ):

Martin Nicklasson, CEO
Phone: +46 8 697 20 00

Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
E-mailerik.kinnman@sobi.com

Swedish Orphan Biovitrum may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on July 6, 2010 at 8:30 a.m.
CET.

[HUG#1429736]

Press release July 6, 2010:

http://hugin.info/134557/R/1429736/376773.pdf

This announcement is
distributed by Thomson Reuters on behalf of Thomson Reuters clients. The
owner of this announcement warrants that: (i) the releases contained
herein are protected by copyright and other applicable laws; and (ii)
they are solely responsible for the content, accuracy and originality of
the information contained therein. All reproduction for further
distribution is prohibited.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE

Copyright 2010, Market Wire, All rights reserved.

Swedish Orphan Biovitrum AB (publ): Swedish Orphan Biovitrum and Dongbao announce Commercial Alliance for the Chinese and European markets

Stockholm, Sweden and Tonghua, China – July 6, 2010 – Swedish Orphan Biovitrum (STO:
SOBI) and Dongbao today announced their intent to form a strategic Commercial Alliance.
In such an alliance, Swedish Orphan Biovitrum would be the marketing and sales partner
of choice for Dongbao’s pipeline of Biopharmaceuticals and other drugs in Europe and
Dongbao would be the marketing and sales partner of choice for Swedish Orphan
Biovitrum’s marketed and pipeline products in China.

The announced Commercial Alliance would be a partnership where both parties will benefit
in two ways. First, each party secures a marketing and sales partner for its own
products in an important new territory, China in the case of Swedish Orphan Biovitrum
and Europe in the case of Dongbao. Second, each party gains access to a new portfolio
of exciting products for its home markets.

The parties also announced that they intend to complete the first stage of the
Commercial Alliance by completing ongoing negotiations regarding the following
products:

*

Iron Sucrose from Dongbao where Swedish Orphan Biovitrum will be the exclusive marketing
and sales partner in Europe for this product.

*

Kineret and the late stage development project Kiobrina from Swedish Orphan Biovitrum
where Dongbao will be the exclusive marketing and sales partner in China for these
products.

Swedish Orphan Biovitrum intends to deepen its collaboration with Dongbao, including its
affiliate Rechon Life Science Group, as regards manufacturing services.

An alliance will address current pharmaceutical market trends in both China and Europe.
The Chinese pharmaceutical market is large and rapidly growing. It is also becoming
more and more receptive to high value, innovative products that meet significant unmet
medical needs. Thus, Swedish Orphan Biovitrum’s products are a good fit with the strong
and growing high value, specialty segment of the Chinese market. Similarly, the
Biosuperior segment of the European pharmaceutical market is rapidly growing. Again,
this makes market entry in Europe for Dongbao’s portfolio of Biosuperiors timely and
in-line with regional trends.

Martin Nicklasson, CEO of Swedish Orphan Biovitrum stated “We are very pleased to have
identified a partner in Dongbao with a successful track record of selling high value
biotechnology products in China. Dongbao has a deep understanding of biotechnology
products from a manufacturing and clinical development perspective. Moreover, they have
an impressive track record of success in regulatory affairs as well as in marketing and
sales. Thus, we see Dongbao as the perfect partner to help Swedish Orphan Biovitrum to
realize the significant opportunity for our products in the Chinese market.

Additionally, we are excited about gaining access to Dongbao’s pipeline of high value
Biosuperiors. We look forward to working with these products over the long term to
realize the full commercial potential of these products in Europe.”

Dr. Zhaoqi Li, Vice President of Dongbao Enterprise Group and the Chairman of the Board
of Rechon Life Science Group expressed that “A fast growing Chinese market is now
offering great opportunity for innovative and high value pharmaceutical products. We
admire Swedish Orphan Biovitrum’s remarkable efforts and achievements in the development
of specialist pharmaceutical products for rare diseases. We will contribute, with the
best of our effort, to the successful introduction of Swedish Orphan Biovitrum’s product
into the Chinese market as well as into the emerging markets where Dongbao/Rechon
already have a strong network established.

It has been a very interesting journey made by Dongbao in the development of high value
biotech products. By combining Swedish Orphan Biovitrum’s knowledge, experience and
market network with Dongbao’s interesting range of biotech products we will have a
prosperous future in Europe.

Partnership has always been important for Dongbao’s business success. The establishment
of a strong collaboration with Swedish Orphan Biovitrum will add good value for our
future development. We are very excited that such a Commercial Alliance with Swedish
Orphan Biovitrum will enable smooth access of our products into the European market and,
in the other direction, we are very pleased to offer our support for the successful
entry of Swedish Orphan Biovitrum’s products into the Chinese market.”

About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with
an international market presence. The company is focused on providing and developing
specialist pharmaceuticals for rare disease patients with high medical needs. The
portfolio consists of about 60 marketed products and an emerging late stage clinical
development pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune
diseases, fat malabsorption, cancer supportive care and inherited metabolic disorders.

Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately
500 employees. The head office is located in Sweden and the share (STO: SOBI) is listed
on NASDAQ OMX Stockholm. For more information please visit www.sobi.com
http://www.sobi.com/ .

For more information please contact: Swedish Orphan Biovitrum AB (publ):

Martin Nicklasson, CEO
Phone: +46 8 697 20 00

Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
E-mail erik.kinnman@sobi.com mailto:erik.kinnman@sobi.com

Swedish Orphan Biovitrum may be required to disclose the information provided herein
pursuant to the Swedish Securities Markets Act. The information was provided for public
release on July 6, 2010 at 8:30 a.m. CET.

HUG#1429736

Press release July 6, 2010 http://hugin.info/134557/R/1429736/376773.pdf

Small Bone Innovations, Inc.Ranked #24 in VentureSource Survey to Identify Top 50 US Based Venture Capital-Backed Companies

NEW YORK–(Business Wire)–
Small Bone Innovations, Inc. (SBi), a leading privately-held orthopedic company
focused exclusively on technologies and treatments for the small bones & joints,
ranked #24 on a survey conducted by Dow Jones VentureSource and published in The
Wall Street Journal (both owned by News Corporation) to identify the Top 50
venture capital-backed U.S. companies. Additionally, SBi was one of the seven
(7) Healthcare companies and the only Orthopedic company to be ranked in the Top
50.

Almost 5,200 VC-backed firms were analyzed by VentureSource by assessing the
track record of a company`s founders, management and investors, the amount of
capital raised in the past three years and the percentage change in the
company`s valuation in the 12 months ending November 30, 2009. The survey was
published by The Wall Street Journal on March 9, 2010.

Anthony G. Viscogliosi, SBi Chairman & CEO, noted: “This ranking rewards the
efforts of our employees and stakeholders for producing innovative products and
underlines the value of our strategy to identify and leverage surgeon and
patient demand for better small bone and joint treatments, especially total
ankle arthroplasty.”

Achievements

2007

Frost & Sullivan selected SBi as the recipient of its 2007 Frost & Sullivan
Award for Entrepreneurial Company of the Year.

SBi was named as one of the Red HerringGlobal 100 – a group of the most
promisingtechnology companies in the world – selected from a list of 1800
entrants.

2006

SBi was named in the Red Herring North America 100, recognizing SBi as one of
the nation`s leading technology companies and the only orthopedic device company
selected.

SBi`s Artelon CMC-I Spacer, developed for patients with osteoarthritis at the
base of the thumb, was named by Medical Design Technology magazine in its 2006
“Year of Innovation” review as one of the most fascinating technologies in the
medical device industry.

Medical Device & Diagnostic Industry magazine named SBi to its list of “50
Companies to Watch” in 2006, noting, “Small Bone Innovations is going against
the grain in its determination to become a market leader in the small bone &
joint device sector.”

About Small Bone Innovations, Inc.

Small Bone Innovations, Inc. (SBi) was founded in 2004 by Viscogliosi Brothers,
LLC, (VB), a New York-based merchant banking firm that specializes in the
musculoskeletal/orthopedics sector. VB created SBi as the first company to focus
purely on small bones & joints. By integrating established companies and
professionals in the field, SBi offers a broad, clinically proven portfolio of
products and technologies to treat trauma and diseases in small bones & joints.
Today, SBi has facilities in New York, NY, Morrisville, PA, Bourg-en-Bresse,
France, Donaueschingen, Germany, and Kuala Lumpur, Malaysia.

For more information on SBi, please visit: www.totalsmallbone.com

Forward-looking statements

This news release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting SBi`s business including increased
competition; the ability of SBi to expand its operations and to attract and
retain qualified professionals; technological obsolescence; general economic
conditions; and other risks.

Small Bone Innovations, Inc.
Varun Gandhi, 212-583-0370 ext. 2126
vgandhi@totalsmallbone.com

Copyright Business Wire 2010

TaiSPO Stars: Sportsman Corp. Launches Turbo Tent

TAIPEI, Taiwan–(Business Wire)–
One of Taiwan’s leading tent manufacturers, Sportsman Corp., recently launched a
series of innovative products to transform the outdoor camping experience.

The 30-second Turbo tent offers outdoor enthusiasts a rapidly pitching tent that
combines innovative design with technology. Using its patented frame system,
Sportsman Corp. designed a family-sized tent that can be pitched in just a few
minutes. The 30-second Turbo tent is made of exceptionally high-quality,
waterproof Ripstop fabric, proven to resist the heaviest rain whilst remaining
tape-sealed to prevent wind-leakage.

Sportsman Corp, which has manufactured tents in Taiwan since 1975, also offers
the brand new Turbo Canopy – a specially designed lightweight, compact-packing
shelter. An optional sunroom can be easily clipped to the frame, providing a
sheltered, shaded area for meals and relaxation. Whether you are planning an
expedition into the bush or just getting away for a weekend, the Turbo Tent is
the perfect choice for happy campers.

Sportsman Corp. has developed over 100 different styles of tent, ranging from
lightweight one-man designs, weighing no more than 1kg, to heavy-duty military
canvas tents weighing up to 200kg.

Visit Sportsman Corp. in TaiSPO (Taipei International Sporting Goods Show) from
29 April to 2 May, 2010 at NANGANG Exhibition Hall.

More information please go to http://www.taispo.com.tw

To pre-register online, please visit

http://www.taispo.com.tw/en_US/member/visitor/preregister.html

Photo:

http://www.cna.com.tw/postwrite/cvpread.aspx?ID=54975

TAITRA
Valentina Pien, 886-2-2725-5200 ext. 2865
valentina@taitra.org.tw

Copyright Business Wire 2010

Telstra announces executive reshuffle

Telstra has announced changes to its executive team, which the telco says is to better align the company’s leadership structure and strategic priorities.

Former Hewlett Packard executive Gordon Ballantyne has been appointed as the new group managing director of consumer and channels.

Mr Ballantyne takes over from acting consumer boss, Glenice Maclellan, who resigned due to personal reasons.

Kate McKenzie will move from strategic marketing, to the newly-created position of chief marketing officer and Robert Nason will become manager of customer experience.

In a letter to the Australian Securities Exchange, Telstra chief executive David Thodey said the changes consolidate the company’s top executives into the four main groups of customer sales and support; product and marketing innovation; operations; and corporate support.

“Telstra’s core objectives are to provide our customers with innovative products and services, and to serve our customers better than anybody else,” he said.

“This reorganisation is designed to get the right people and processes in place.

It will enable us to better deliver Australians the services and products they want and to profitably grow our business domestically and internationally.”

Mr Thodey also announced the resignation of BigPond chief, Justin Milne, effective from the start of June.

It is Telstra’s second executive reshuffle since last November, and comes as the telco continues negotiations with the Federal Government over its involvement in the National Broadband Network.

Telstra’s shares have risen since the news was announced, at 11:05 am (AEDT) they were at $3.09.

Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year…

Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full
Year 2009 Results

CHARLOTTE, N.C., March 3, 2010 (GLOBE NEWSWIRE) — Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) announced that it will release fourth quarter
and full year results for the period ended December 31, 2009 after the market
closes on Wednesday, March 10, 2010. Chelsea management will host a conference
call and live webcast to discuss these financial results and provide an update
on each of its development programs that afternoon at 4:30 PM ET.

Interested investors may participate in the conference call by dialing
877-638-9567 (domestic) or 720-545-0009 (international). A replay will be
available for one week following the call by dialing 800-642-1687 for domestic
participants or 706-645-9291 for international participants and entering
passcode 60600587 when prompted. Participants may also access both the live and
archived webcast of the conference call on Chelsea’s web site at
www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires
and develops innovative products for the treatment of a variety of human
diseases. Chelsea’s most advanced drug candidate, Droxidopa, is an orally active
synthetic precursor of norepinephrine initially being developed for the
treatment of neurogenic orthostatic hypotension. In addition to Droxidopa,
Chelsea is also developing a portfolio of metabolically inert oral antifolate
molecules engineered to have potent anti-inflammatory and anti-tumor activity to
treat a range of immunological disorders, including two clinical stage product
candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior
safety and tolerability, as well as increased potency versus methotrexate (MTX).

This press release contains forward-looking statements regarding future events.
These statements are just predictions and are subject to risks and uncertainties
that could cause the actual events or results to differ materially. These risks
and uncertainties include reliance on collaborations and licenses, risks and
costs of drug development, regulatory approvals, intellectual property risks,
our reliance on our lead drug candidate CH-1504, our history of losses and need
to raise more money, competition, market acceptance for our products if any are
approved for marketing, reliance on key personnel including specifically Dr.
Pedder, management of rapid growth, and the need to acquire or develop
additional products.

CONTACT: Chelsea Therapeutics
Investors & Media:
Kathryn McNeil
718-788-2856
mcneil@chelseatherapeutics.com

InfoPrint boosts solutions developer program with support for InfoPrint ProcessDirector partners

Bangalore, June 29 (ANI/Business Wire India): InfoPrint Solutions Company, a joint venture between IBM and Ricoh, today announced a major enhancement to its developer support program, aimed at enabling partners to test and integrate new components into InfoPrint ProcessDirector (IPPD), the flagship output management workflow system.

This developer program extension creates a systematic and programmatic way for independent software vendors (ISVs) who want to expand IPPD functionality to interact with the InfoPrint technical team and InfoPrint development support resources.

Larger ISVs can extend their packaged offering by being able to market with print workflow software, while smaller ISV partners gain additional reach by selling their components as part of IPPD bids.

The program includes several elements such as an integration guide, written samples, case studies and technical tutorials for partners.

Users gain access to an external development system, or a loan of the required software for testing purposes. Placing a focus on ongoing learning, InfoPrint also offers an education series and technical support to all participating partners.

This also builds on the services offered via the InfoPrint Solutions Developer Program, such as InfoPrint’s Virtual Print Facility (VPF).

This innovative function provides partner developers with remote access to InfoPrint’s high-speed production machines, enabling real-time testing of generated print data streams.

“Enabling our partners to test and integrate their offerings with our core workflow products means that we go to market with the best solutions possible, that will meet current business demand and ensure customers remain competitive,” said Enrico Parodi, Vice President WW Software and Services.

‘Through working to support our established partnerships, we continue to bring our customers the most innovative products and services,” added Parodi. (ANI)

‘Tata group innovating affordable products for masses’

angalore, May 27 (IANS) As part of its commitment to address the lower part of the pyramid, the Rs.150,000-crore Tata group is innovating affordable products for the masses, its chairman Ratan Tata said here Wednesday.

“We have taken a conscious decision to innovate products that are affordable for the masses, which account for about 70 percent of our population,” Tata told students of the premier Indian Institute of Science (IISc) here.

“Nano car, Nano housing and Ginger budget hotels from our group are some of the innovative products meant for the mass market.”

Interacting with the institute’s faculty and students at the valedictory function of its centenary celebrations, Tata said as very few corporations addressed this section of society, the Tata group had taken the challenge of creating products that meet the aspirations of the masses.

“All along, the focus of entrepreneurs and corporations has been to develop products for the top of the pyramid that has about 250-300 million people. Though these people constitute about 25-30 percent of the population, the need of the hour is to create products and services for the rest of the 1.2-billion Indians,” he said.

Expressing hope that similar innovations would come out of the century-old IISc, Tata said its faculty and students should strive to create new technologies and products that address the needs of the masses and improve quality of living.

“Though we do not mandate what the faculty and research students should do, I am confident innovations will come out of the institute that will benefit the majority.”

Lamenting that very few organisations have taken the risk of developing new technologies for the masses, Tata said his group had created new opportunities and challenges through diversification and acquisitions.

“We acquired Jaguar to have a global activity as we cannot have it here (India) on the basis of our volume or scale,” he added.

Airtel introduces new BlackBerry service plan

Mumbai, Mar 3 (ANI/Business Wire India): Airtel and Research In Motion (RIM) today introduced a new service plan specifically for Airtel customers in India.

The BlackBerry Personal Mail service plan is an innovative offering that provides Airtel customers with unlimited email and instant messaging (IM) on BlackBerry smartphone for just Rs. 499 per month.

It is the first service plan priced at less than Rs. 500 to offer unlimited email and IM to BlackBerry smartphone customers in the Indian market.

“It is our strategic intent and single minded focus to consistently offer innovative products and services that deliver convenience and value to our customers,” said Sanjay Gupta, Chief Marketing Officer, Mobile Services, Airtel.

“With the BlackBerry Personal Mail service plan, we are extending the market to a wider segment, allowing customers such as young professionals, small business owners and students to access their email on the move and stay seamlessly connected with instant messaging on their BlackBerry smartphones,” Sanjay added.

Frenny Bawa, Vice President, India at Research In Motion said, “We are pleased to work with Airtel to bring the rich communications features and unique user experience offered by the BlackBerry solution in a unique offering to customers in India. The new BlackBerry Personal Mail service plan from Airtel is an attractive offering that will enable more users to choose and enjoy BlackBerry smartphones.”

The BlackBerry Personal Mail service plan offers unlimited access to the industry-leading email and instant messaging features on the BlackBerry platform, allowing Airtel customers to access up to 10 supported POP3/IMAP email accounts (including most popular ISP email accounts such as Yahoo! Mail and Google Mail) as well as various instant messaging services (including Windows Live Messenger, GTalk, Yahoo! Messenger and BlackBerry Messenger) from single device. (ANI)

Bharti Airtel starts mobile services in Sri Lanka

Colombo, Jan 12 (ANI/Business Wire India): Bharti Airtel Lanka (Pvt.) Ltd today announced the launch of its mobile services in Sri Lanka under the Airtel brand.

The services have been launched on a state-of-the-art 3.5G network.

Airtel has launched a suite of innovative services and redefined affordability by offering attractive call rates. What truly sets these tariff plans apart is the simplicity and ease of understanding for the customer, including features such as unconditional free incoming calls.

Airtel’s simple tariffs liberate the customer from the concept of peak and off-peak call rates by offering standard tariffs throughout the day and allowing them to speak freely.

For the first time, Sri Lankan mobile customers will not have to bother with within network and outside network concept as Airtel will offer uniform call charges to any network.

The company will also offer unique and customer relevant Value Added Services.

On the occasion Sunil Bharti Mittal, Chairman and Managing Director, Bharti Airtel said, “We are extremely honoured to present Airtel to Sri Lanka. At Bharti, we have always believed in undertaking business projects that are transformational and have a positive impact on the society at large. Bharti Airtel has also set global benchmarks in telecom services, be it our unique business model based on outsourcing or innovative products and services.”

“We are delighted at being given this opportunity to serve the people of Sri Lanka and contribute to the growth story of the country. It will be Airtel’s sincere endeavour to drive affordability in the Sri Lankan market and empower more and more people to experience the benefits of mobile internet and telephony. We are confident that with our experience of serving around 88 million customers, we will make a positive impact on the telecom landscape of Sri Lanka,” Mittal added.

Bharti Airtel plans to invest around USD 200 million in its Sri Lanka operations. In just over an year, the company has commissioned a sizeable state-of-the-art network.

This is the fastest network roll-out of its scale by any mobile operator in Sri Lanka. This will enable Bharti Airtel to fulfill its promise of providing world-class mobile services at affordable rates to customers in Sri Lanka.

In line with the innovative business model based on outsourcing that it pioneered, Bharti Airtel has created an ecosystem of partners for its Sri Lanka operations.

It has entered into a three-year managed network deal with Huawei, partnered with IBM to manage its comprehensive IT infrastructure and application requirements, and selected iSmart Timex as its customer care partner. (ANI)